ImmunoMolecular Therapeutics
Latest round
- Series A
Last raised
- Oct 2019
Total raised
- $10M
Investors
- 3
About ImmunoMolecular Therapeutics
Based in Colorado, US, ImmunoMolecular Therapeutics, Inc. operates as a clinical-stage company that develops oral drug therapies for autoimmune disease against human leukocyte antigen (HLA) variants.
Who invested in ImmunoMolecular Therapeutics
3 investors across 1 round
See all investors in ImmunoMolecular Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 9, 2019
Amount
$10M
Investors
Questions about ImmunoMolecular Therapeutics
Who invested in ImmunoMolecular Therapeutics?
ImmunoMolecular Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImmunoMolecular Therapeutics raised?
ImmunoMolecular Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ImmunoMolecular Therapeutics last raise money?
ImmunoMolecular Therapeutics's most recent round on record is a Series A, in Oct 2019.
What does ImmunoMolecular Therapeutics do?
Based in Colorado, US, ImmunoMolecular Therapeutics, Inc.
Where is ImmunoMolecular Therapeutics headquartered?
ImmunoMolecular Therapeutics is headquartered in Aurora, US.
Which VCs invest in companies like ImmunoMolecular Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ImmunoMolecular Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ImmunoMolecular Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.